AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05467436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetics, IV sedation drugs and analgesics.
Description: Personalized prescription for local anesthetics, IV sedation drugs and analgesics, based on pharmacogenomic assesment, social, dietary and medication history
Study NCT02062879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine administered as patient-controlled analgesia.
Study NCT02062879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone administered as patient-controlled analgesia.
Study NCT05713045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Konakion
Description: Comparing 4 different regimen of Vitamin K administration in newborn
Study NCT02314650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupoint stimulation
Description: stimulation was given at acupoints
Study NCT02314650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-acupoint stimulation
Description: stimulation was given at non-acupoints
Study NCT02314650 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electrodes attached
Description: electrode were attached to skin
Study NCT02314650 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: electrodes attached
Description: electrode were attached to skin
Study NCT02314650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrodes attached
Description: electrode were attached to skin
Study NCT01067014 — intervention group
Intervention type: DEVICE
Intervention: Baxano iO-Flex® System
Description: Decompressive lumbar surgery using Baxano iO-Flex® System
Study NCT03755687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy Intervention
Description: Standardized mixed media art directives.
Study NCT05603689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isocaloric ketogenic diet
Description: The ICKD definition was based on the works of Sansone (2018) and Trimboli (2020). We defined ICKD as a daily CHOs ingestion \< 30 to 50 g.d-1, without any limitation in fat consumption. Participants self-selected their own diet based on a list of advised and forbidden foods developed to fit the definition of ICKD. There were no instructions to limit calories.
Study NCT05603689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric ketogenic diet
Description: The ICKD definition was based on the works of Sansone (2018) and Trimboli (2020). We defined ICKD as a daily CHOs ingestion \< 30 to 50 g.d-1, without any limitation in fat consumption. Participants self-selected their own diet based on a list of advised and forbidden foods developed to fit the definition of ICKD. There were no instructions to limit calories.
Study NCT03510520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medium Cut-Off Haemodialysis
Description: Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months
Study NCT03510520 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: On-Line Haemodiafiltration
Description: Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)
Study NCT02286505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Morphometry
Description: Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
Study NCT02286505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard radiological assessment
Description: Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
Study NCT02286505 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard radiological assessment
Description: Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
Study NCT01969877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Study NCT00651326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT00651326 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: 46 Gy in 23 fractions over \< 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over \< 3 weeks
Study NCT00651326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study NCT03788811 — intervention group
Intervention type: DEVICE
Intervention: ERG assessment (RSPA)
Description: Processing and analysis of retinal signals
Study NCT02008981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Study NCT00130221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate impregnated cloth
Study NCT00130221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily bathing with Bar soap
Description: bathed daily with bar soap (Dial Corp., Scottsdale, AZ), warm water, and cotton washcloths.
Study NCT03459963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: indwelling urinary catheter
Description: 85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
Study NCT01969877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT05158985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phonophoresis
Description: treatment
Study NCT05158985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: treatment
Study NCT04515368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunization
Description: Immunisation with one of four licensed vaccines
Study NCT03964753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel and Cisplatin
Description: Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
Study NCT03964753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: surgery
Study NCT03964753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgery
Study NCT02713529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG820 and pembrolizumab
Description: Treatment with AMG820 and pembrolizumab
Study NCT00068510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Study NCT04297969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: objective pediatric vision screen GCK glow fixation
Description: 2-axis, smart phone flash concentrated photoscreen using novel, low-detail, color glow fixation device
Study NCT02225912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrevinC
Study NCT02225912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02644902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avatar assisted cascade training
Description: Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
Study NCT02644902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialist led training in THP
Description: Training and supervision of lady health workers by specialists as in original THP
Study NCT03512431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Micro sampling
Description: Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
Study NCT01213823 — intervention group
Intervention type: OTHER
Intervention: Does not apply
Description: This is a non-interventional study, therefore the intervention type / name do not apply
Study NCT02001896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine; cisplatin or carboplatin; erlotinib
Study NCT02001896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Study NCT00595933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sugar-free chewing gum
Description: Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
Study NCT00595933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
Study NCT00595933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouth rinse
Description: Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire
Study NCT00595933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mouth rinse
Description: Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
Study NCT00595933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mouth spray
Description: Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
Study NCT00595933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mouth spray
Description: Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
Study NCT00993733 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous haemodiafiltration
Description: Dialysis procedure administrated to the patients with acute renal failure
Study NCT03627169 — intervention group
Intervention type: DEVICE
Intervention: MATRx plus
Description: The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
Study NCT00420173 — intervention group
Intervention type: PROCEDURE
Intervention: Laboratory analysis
Description: blood withdrawal
Study NCT01680627 — intervention group
Intervention type: BEHAVIORAL
Intervention: CASI
Study NCT00797680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 72 hours hypothermia
Description: 72 hours mild hypothermia (33 +/1 1 degree Celsius)
Study NCT00797680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24 hours hypothermia
Description: 24 hours mild hypothermia (33 +/1 1 degree Celsius)
Study NCT01565564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared glycaemic control care within the local three-tier's antenatal care network
Description: * Individualized dietary and physical activity consultation plus group diabetes education~* Self blood glucose monitoring~* Insulin therapy if indicated~* Self blood glucose monitoring~* Insulin therapy institutions if indicated;
Study NCT03453866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warmed Arthroscopic Fluids
Description: Warmed Arthroscopic Fluids
Study NCT03453866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Room Temperature Arthroscopic Fluids
Description: Room Temperature Arthroscopic Fluids
Study NCT03582904 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: real or sham tDCS delivered to primary motor cortex
Study NCT03582904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: real or sham tDCS delivered to primary motor cortex
Study NCT03781791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Investigational Treatment ENT-01
Description: ENT-01 will be administered in tablet form, once daily.
Study NCT03781791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment
Description: Placebo will be administered in tablet form, once daily.
Study NCT00276614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT03324425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 80mg
Description: Participants will receive simvastatin 80 mg by mouth daily at bedtime
Study NCT04469231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy & Fusion
Description: ACDF
Study NCT00806442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Borage Seed Oil and Echium Seed Oil
Description: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
Study NCT00806442 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn Oil
Description: 9 g/day of corn oil
Study NCT02692599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: investigational live attenuated mumps vaccine
Description: The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
Study NCT03945019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13 SC (Infliximab)
Description: Subcutaneous injection of CT-P13 SC
Study NCT03945019 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Subcutaneous injection of Placebo SC
Study NCT05729698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baby warmer swaddle
Description: Baby Swaddle with Heating System
Study NCT05729698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polyethylene bag
Description: polyethylene food bag
Study NCT00744666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 1% topical eye drops
Description: Prednisolone 1% 1gtt qid to the eye requiring IVTA
Study NCT01077193 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastric Plication
Description: A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
Study NCT01468389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 900-1000mg/m2 bid, days 1-14, every 3 weeks
Study NCT01468389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
Study NCT02203006 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: OVIHD
Description: 7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
Study NCT03588949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement with L-carnitine (FertilHom)
Description: 1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
Study NCT03588949 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Dietary Supplement
Description: 1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
Study NCT04665115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT04665115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01407523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * Formulation: concentrate for solution for infusion~* Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~* Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~* Frequency: twice daily
Study NCT01522404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
Study NCT01522404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
Study NCT01522404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
Study NCT01522404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
Study NCT03734029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (DS-8201a)
Description: DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
Study NCT03734029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study NCT03734029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study NCT03734029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study NCT01469637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfamethoxazole + MMX placebo
Description: 800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
Study NCT01469637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole + MMX Mesalazine/mesalamine
Description: 800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
Study NCT03225027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional judgment task
Description: Participants had to indicate on a computer the emotional intensity of audio recordings.
Study NCT03734029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study NCT03225027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-experimental questionnaire
Description: Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
Study NCT03734029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study NCT03156959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
Study NCT03156959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-Eb
Description: The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself.
Study NCT03156959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-Eb
Description: The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself.
Study NCT04921540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ingrown toenails with surgery with chemical cauterisation
Description: Removal of the ingrown lateral part of the toenail and chemical cauterisation
Study NCT00227513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00227513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally